NEW YORK (TheStreet) -- Several small-cap stocks were poised to move on above-average volume during Monday's session.
Tellabs (TLAB Quote) slumped by 26 cents, or 3.9%, to $6.40 in the premarket session after the company said it swung to a third-quarter profit of $29 million, or 7 cents a share, compared with a year-ago loss of $999 million, or $2.51 a share. Revenue slid 8.3% from a year ago to $389 million. Analysts were looking for a profit of 6 cents a share on $394 million in sales, according to Thomson Reuters. Tellabs said it expects fourth-quarter revenue to be flat, plus or minus 3%. The three-month average daily volume for Tellabs is 9.2 million, according to Yahoo! Finance. Elron Electronic Industries (ELRN Quote) surged by $1.18, or 19.4%, to $7.26 in the premarket session after the company said it has received a non-binding indication of interest from a third party regarding a potential acquisition of Medingo, an Elron subsidiary. The three-month average daily volume for Elron is 116,000, according to Yahoo! Finance. Matrixx Initiatives (MTXX Quote) dropped by 63 cents, or 12.5%, to $4.40 in the premarket session after the company said the Food and Drug Administration has recently indicated it is unwilling to reverse its position regarding Zicam Cold Remedy nasal gel products. In June, Matrixx said the FDA issued a letter to the company with concerns about the marketing of Zicam. Matrixx will report earnings after the closing bell Monday. The three-month average daily volume for Matrixx is 1 million, according to Yahoo! Finance. SuperGen (SUPG Quote) jumped by 52 cents, or 21.9%, to $2.90 in the premarket session after the company said it will enter into a multi-year collaboration with GlaxoSmithKline (GSK Quote) to discover and develop cancer therapeutics based on epigenetic targets. In connection with the transaction, SuperGen said it will receive $5 million upfront, inclusive of a $3 million common stock investment, priced at a premium to market. The three-month average daily volume for SuperGen is 232,000, according to Yahoo! Finance. Arena Pharmaceuticals (ARNA Quote) rose by 41 cents, or 9.5%, to $4.75 in the premarket session after the company said that data from the its BLOOM, or Behavioral modification and Lorcaserin for Overweight and Obesity Management, Phase 3 trial demonstrate its drug candidate Lorcaserin significantly increased excess weight loss, improved markers of cardiovascular risk and glycemic parameters, and was not associated with depression or suicidal ideation. The three-month average daily volume for Arena is 4.9 million, according to Yahoo! Finance. -- Written by Robert Holmes in New York. Check out all of Monday's high-volume, under-$5 stocks at the Dollar Store Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
-
Honda issues global airbag recall
BBC
-
China Passes Germany as Worlds Top Exporter
New York Times
-
Ore Increases Boost Steel Prices
The Wall Street Journal.
-
Europe Weighs Rescue Plan for Greece
WSJ.com: Asia Home
-
U.S. Stocks Rally on Growing Prospects for Bailout of Greece
BusinessWeek Online
-
Clive Palmer Clarifies His $60B China Coal Sale
Forbes.com: Business News
-
Storm over bailout of Greece, EU's most ailing economy
Latest Business News from Times Online
-
Square Feet: Changing a Culture by Removing Walls
New York Times
-
Paulson Tells Buffett Banks to Repay ‘Every Penny’ (Update2)
BusinessWeek Online
-
Tuesday Reads
The Big Picture
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,058.64 | 1,070.52 | 2,150.87 | 36.33 |
Oil *
72.02
|
|
UP
150.25
|
UP
13.78
|
UP
24.82
|
UP
0.41
|
10 Yr
3.63%
SPDR Gold
105.45
|
|
+1.52%
|
+1.30%
|
+1.17%
|
+1.14%
|
Data delayed 20 minutes |
More From TheStreet
Latest HeadlinesBrokerage Partners
Sponsored Links














